Covid-19 roundup: Alexion's C5 inhibitor Ultomiris misses the PhIII bar; Lonza in waiting game to use ingredients in Moderna vaccine
C5 inhibition isn’t the answer to the search for treatments for severe Covid-19 after all.
Alexion is pausing enrollment to a Phase III study testing Ultomiris, the long-acting follow-on to Soliris, among patients requiring mechanical ventilation after the independent data monitoring committee raised a lack of efficacy in an interim analysis. Among 122 patients (out of a planned enrollment of 270), there was no meaningful difference in survival at Day 29.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.